Search | VHL Regional Portal

Outcomes and characteristics of nonmelanoma skin cancers in patients with myeloproliferative neoplasms on ruxolitinib.

Rampotas, Alex; Carter-Brzezinski, Luke; Somervaille, Tim C P; Forryan, James; Panitsas, Fotios; Harrison, Claire; Witherall, Ruth; Innes, Andrew J; Wallis, Louise; Butt, Naumann M; Psaila, Bethan; Mead, Adam J; Carter, Matthew; Godfrey, Anna L; Laing, Heather; Garg, Mamta; Francis, Sebastian; Ewing, Joanne; Teh, Chun Huat; Cowen, Hannah Bibi; Dyer, Peter; McConville, Conall; Wadelin, Frances; Sahra, Ali; McGregor, Andrew; Kulakov, Elizabeth; McLornan, Donal P; Lambert, Jonathan.

Blood ; 143(2): 178-182, 2024 Jan 11.

Article in English | MEDLINE | ID: mdl-37963262

ABSTRACT

ABSTRACT: Nonmelanoma skin cancers (NMSCs) in ruxolitinib-treated patients with myeloproliferative neoplasms behave aggressively, with adverse features and high recurrence. In our cohort, mortality from metastatic NMSC exceeded that from myelofibrosis. Vigilant skin assessment, counseling on NMSC risks, and prospective ruxolitinib-NMSC studies are crucial.

Subject(s)

Myeloproliferative Disorders , Pyrazoles , Pyrimidines , Skin Neoplasms , Humans , Prospective Studies , Myeloproliferative Disorders/drug therapy , Nitriles , Skin Neoplasms/drug therapy

ABSTRACT

Subject(s)

SEND TO:

SELECTION OF CITATIONS

SEARCH DETAIL